Prime Medicine Earnings Estimate

Etfs . USA . 
Etf . Prime Medicine Common
PRME Etf  USD 4.18  0.25  5.64%   
By analyzing Prime Medicine's earnings estimates, investors can diagnose different trends across Prime Medicine's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Prime Medicine Common is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Prime Medicine is projected to generate -0.32085 in earnings per share on the 31st of December 2025. Prime Medicine earnings estimates show analyst consensus about projected Prime Medicine Common EPS (Earning Per Share). It derives the highest and the lowest estimates based on Prime Medicine's historical volatility. Many public companies, such as Prime Medicine, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Prime Medicine's earnings estimates, investors can diagnose different trends across Prime Medicine's analyst sentiment over time as well as compare current estimates against different timeframes.
  
Build AI portfolio with Prime Etf
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prime Medicine Common. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Prime Medicine Earnings per Share Projection vs Actual

About Prime Medicine Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Prime Medicine earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Prime Medicine estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Prime Medicine fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America

Other Information on Investing in Prime Etf

Prime Medicine financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY